488143879	488143879	CD	B-NP	O
|	|	NNP	I-NP	O
SEH	SEH	NNP	I-NP	O
|	|	VBD	B-VP	O
85427112	85427112	CD	B-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
7725862	7725862	CD	B-NP	O
|	|	CC	I-NP	O
11/20/2004	11/20/2004	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Summary	Summary	NNP	I-NP	O
|	|	NNP	I-NP	O
Signed	Signed	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
5/23/2004	5/23/2004	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
ATTENDING	ATTENDING	NNP	B-NP	O
:	:	:	O	O
JARED	JARED	NNP	B-NP	O
ELIAS	ELIAS	NNP	I-NP	O
ARICHABALA	ARICHABALA	NNP	I-NP	O
M.D.	M.D.	NNP	I-NP	O
GMS	GMS	NNP	I-NP	O
Goment	Goment	NNP	I-NP	O
Nahpo	Nahpo	NNP	I-NP	O
SERVICE	SERVICE	NNP	I-NP	O
DATE	DATE	NNP	I-NP	O
OF	OF	NNP	I-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
:	:	:	O	O
To	To	TO	B-VP	O
be	be	VB	I-VP	O
determined	determine	VBN	I-VP	O
.	.	.	O	O

CHIEF	CHIEF	NN	B-NP	B-protein
COMPLAINT	COMPLAINT	NN	I-NP	O
:	:	:	O	O
Increased	Increase	VBN	B-NP	O
dyspnea	dyspnea	NN	I-NP	O
on	on	IN	B-PP	O
exertion	exertion	NN	B-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
This	This	DT	B-NP	O
62-year-old	62-year-old	JJ	I-NP	O
male	male	NN	I-NP	O
with	with	IN	B-PP	O
morbid	morbid	NN	B-NP	O
obesity	obesity	NN	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
chronic	chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
,	,	,	O	O
prior	prior	JJ	B-NP	O
MI	MI	NN	I-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
increased	increase	VBN	B-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
edema	edema	NN	I-NP	O
and	and	CC	I-NP	O
dyspnea	dyspnea	NN	I-NP	O
on	on	IN	B-PP	O
exertion	exertion	NN	B-NP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
last	last	JJ	I-NP	O
several	several	JJ	I-NP	O
months	month	NNS	I-NP	O
.	.	.	O	O

Some	Some	DT	B-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
attributed	attribute	VBN	I-VP	O
to	to	TO	B-PP	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
an	an	DT	B-NP	O
increased	increase	VBN	I-NP	O
creatinine	creatinine	NN	I-NP	O
from	from	IN	B-PP	O
approximately	approximately	RB	B-NP	O
in	in	IN	B-PP	O
early	early	JJ	B-NP	O
February	February	NNP	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
year	year	NN	I-NP	O
to	to	TO	B-PP	O
5.5	5.5	CD	B-NP	O
in	in	IN	B-PP	O
September	September	NNP	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
previously	previously	RB	I-VP	O
refused	refuse	VBN	I-VP	O
dialysis	dialysis	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
agreed	agree	VBD	B-VP	O
a	a	DT	B-NP	O
few	few	JJ	I-NP	O
weeks	week	NNS	I-NP	O
ago	ago	RB	B-ADVP	O
to	to	TO	B-VP	O
begin	begin	VB	I-VP	O
the	the	DT	B-NP	O
process	process	NN	I-NP	O
of	of	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
scheduled	schedule	VBN	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
fistula	fistula	NN	I-NP	B-protein
evaluation	evaluation	NN	I-NP	I-protein
next	next	IN	B-NP	I-protein
week	week	NN	I-NP	I-protein
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
few	few	JJ	I-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
dyspnea	dyspnea	NN	I-NP	O
on	on	IN	B-PP	O
exertion	exertion	NN	B-NP	O
has	have	VBZ	B-VP	O
accelerated	accelerate	VBN	I-VP	O
.	.	.	O	O

Whereas	Whereas	IN	B-SBAR	O
,	,	,	O	O
he	he	PRP	B-NP	O
used	use	VBD	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
walk	walk	VB	I-VP	O
40	40	CD	B-NP	O
to	to	TO	I-NP	O
50	50	CD	I-NP	O
feet	foot	NNS	I-NP	O
without	without	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
is	be	VBZ	B-VP	O
now	now	RB	B-ADVP	O
only	only	RB	B-ADJP	O
able	able	JJ	I-ADJP	O
to	to	TO	B-VP	O
walk	walk	VB	I-VP	O
10	10	CD	B-NP	O
feet	foot	NNS	I-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
he	he	PRP	B-NP	O
is	be	VBZ	B-VP	O
presenting	present	VBG	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
emergency	emergency	NN	I-NP	O
department	department	NN	I-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
got	get	VBD	B-VP	O
his	his	PRP$	B-NP	O
home	home	NN	I-NP	O
CPAP	CPAP	NN	I-NP	O
,	,	,	O	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
on	on	IN	B-PP	O
chest	chest	NN	B-NP	O
x-ray	x-ray	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
of	of	IN	B-PP	O
poor	poor	JJ	B-NP	B-protein
quality	quality	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
to	to	TO	B-VP	O
have	have	VB	I-VP	O
a	a	DT	B-NP	O
question	question	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
lower	low	JJR	I-NP	O
lobe	lobe	NN	I-NP	O
consolidation	consolidation	NN	I-NP	O
and	and	CC	O	O
therefore	therefore	RB	B-VP	O
received	receive	VBD	I-VP	O
one	one	CD	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
ceftriaxone	ceftriaxone	NN	B-NP	O
and	and	CC	I-NP	O
azithromycin	azithromycin	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
BNP	BNP	NN	I-NP	B-protein
was	be	VBD	B-VP	O
elevated	elevate	VBN	I-VP	O
to	to	TO	B-PP	O
1663	1663	CD	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
from	from	IN	B-PP	O
655	655	CD	B-NP	O
one	one	CD	I-NP	O
year	year	NN	I-NP	O
ago	ago	IN	B-PP	O
-RRB-	-RRB-	NN	B-NP	B-protein
and	and	CC	O	O
his	his	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
rose	rise	VBD	B-VP	O
to	to	TO	B-PP	O
5.9	5.9	CD	B-NP	O
from	from	IN	B-PP	O
5.5	5.5	CD	B-NP	O
in	in	IN	B-PP	O
September	September	NNP	B-NP	O
and	and	CC	O	O
4.1	4.1	CD	B-NP	O
in	in	IN	B-PP	O
February	February	NNP	B-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
also	also	RB	B-ADVP	O
an	an	DT	B-NP	O
element	element	NN	I-NP	O
of	of	IN	B-PP	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
renal	renal	JJ	I-NP	O
service	service	NN	I-NP	O
for	for	IN	B-PP	O
consideration	consideration	NN	B-NP	O
of	of	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
and	and	CC	I-NP	O
volume	volume	NN	I-NP	O
removal	removal	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Hypertension	Hypertension	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Diabetes	Diabetes	NN	B-NP	B-protein
type	type	NN	I-NP	I-protein
II	II	CD	I-NP	I-protein
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Morbid	Morbid	JJ	B-NP	O
obesity	obesity	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Sleep	Sleep	JJ	B-NP	O
apnea	apnea	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Chronic	Chronic	JJ	B-NP	O
hydronephrosis	hydronephrosis	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

FSGS	FSGS	NN	B-NP	B-protein
-LRB-	-LRB-	HYPH	I-NP	O
focal	focal	JJ	I-NP	O
segmental	segmental	JJ	I-NP	O
glomerular	glomerular	JJ	I-NP	O
sclerosis	sclerosis	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Status	Status	NNP	B-NP	O
post	post	NN	I-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
for	for	IN	B-PP	O
multiple	multiple	JJ	B-NP	O
myeloma	myeloma	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

BPH	BPH	NN	B-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Prior	Prior	JJ	B-NP	O
MI	MI	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
able	able	JJ	B-ADJP	O
to	to	TO	B-PP	O
cath	cath	NN	B-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-PP	O
body	body	NN	B-NP	B-protein
habitus	habitus	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

10	10	CD	B-NP	O
.	.	.	O	O

Hypercholesterolemia	Hypercholesterolemia	NN	B-NP	O
.	.	.	O	O

11	11	CD	B-NP	O
.	.	.	O	O

Chronic	Chronic	JJ	B-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
baseline	baseline	NN	I-NP	O
creatinine	creatinine	NN	I-NP	O
4.1	4.1	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

ALLERGIES	ALLERGIES	NNS	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
states	state	VBZ	B-VP	O
that	that	IN	B-SBAR	O
aspirin	aspirin	NN	B-NP	O
has	have	VBZ	B-VP	O
given	give	VBN	I-VP	O
him	him	PRP	B-NP	O
a	a	DT	B-NP	O
bleed	bleed	NN	I-NP	O
before	before	IN	B-PP	O
from	from	IN	B-PP	O
his	his	PRP$	B-NP	O
urine	urine	NN	I-NP	O
that	that	WDT	B-NP	O
resolved	resolve	VBD	B-VP	O
when	when	WRB	B-ADVP	O
the	the	DT	B-NP	O
aspirin	aspirin	NN	I-NP	O
was	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Multivitamin	Multivitamin	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Toprol	Toprol	NN	B-NP	B-protein
XL	XL	NN	I-NP	I-protein
100	100	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
q.d.	q.d.	NN	I-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

Lasix	Lasix	NN	B-NP	B-protein
160	160	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
q.d.	q.d.	NN	I-NP	I-protein
4	4	CD	I-NP	I-protein
.	.	.	O	O

Epogen	Epogen	NN	B-NP	O
40	40	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
units	unit	NNS	I-NP	O
q.	q.	NN	I-NP	O
week	week	NN	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Mirapex	Mirapex	NNP	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
,	,	,	O	O
0.5	0.5	CD	B-NP	O
mg	mg	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
6	6	CD	I-NP	O
.	.	.	O	O

Calcitriol	Calcitriol	NN	B-NP	O
0.75	0.75	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
7	7	CD	I-NP	O
.	.	.	O	O

Trazodone	Trazodone	NN	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
insomnia	insomnia	NN	I-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Wellbutrin	Wellbutrin	NN	B-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
9	9	CD	I-NP	O
.	.	.	O	O

Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Bactroban	Bactroban	JJ	B-NP	O
topical	topical	JJ	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
11	11	CD	I-NP	O
.	.	.	O	O

Sotalol	Sotalol	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
12	12	CD	I-NP	O
.	.	.	O	O

Lipitor	Lipitor	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
13	13	CD	I-NP	O
.	.	.	O	O

Sudafed	Sudafe	VBN	B-VP	O
60	60	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.h.s.	q.h.s.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
nasal	nasal	JJ	I-NP	O
congestion	congestion	NN	I-NP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Flomax	Flomax	NN	B-NP	O
0.8	0.8	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
15	15	CD	I-NP	O
.	.	.	O	O

Iron	Iron	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
16	16	CD	I-NP	O
.	.	.	O	O

Afrin	Afrin	NN	B-NP	O
two	two	CD	B-NP	O
puffs	puff	NNS	I-NP	O
p.r.n.	p.r.n.	IN	B-PP	O
17	17	CD	B-NP	O
.	.	.	O	O

Vitamin	Vitamin	NNP	B-NP	O
C.	C.	NNP	I-NP	O
18	18	CD	I-NP	O
.	.	.	O	O

Glipizide	Glipizide	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
19	19	CD	I-NP	O
.	.	.	O	O

Flonase	Flonase	NN	B-NP	B-protein
.	.	.	O	O

20	20	CD	B-NP	O
.	.	.	O	O

Vicodin	Vicodin	NN	B-NP	O
5/500	5/500	CD	I-NP	O
mg	mg	NN	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	RB	B-NP	O
21	21	CD	I-NP	O
.	.	.	O	O

Nasonex	Nasonex	NNP	B-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAM	EXAM	NN	I-NP	O
:	:	:	O	O
Pulse	Pulse	NN	B-NP	O
92	92	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
160/70	160/70	CD	I-NP	O
,	,	,	O	O
respirations	respiration	NNS	B-NP	O
18	18	CD	B-NP	O
,	,	,	O	O
95	95	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
wearing	wear	VBG	I-VP	O
his	his	PRP$	B-NP	O
CPAP	CPAP	NN	I-NP	B-protein
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
falling	fall	VBG	I-VP	O
asleep	asleep	RB	B-ADVP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
interview	interview	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
in	in	IN	B-PP	O
no	no	DT	B-NP	O
apparent	apparent	JJ	I-NP	O
distress	distress	NN	I-NP	O
.	.	.	O	O

Heart	Heart	NNP	B-NP	O
is	be	VBZ	B-VP	O
regular	regular	JJ	B-NP	O
rate	rate	NN	I-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
.	.	.	O	O

Heart	Heart	NN	B-NP	O
sounds	sound	NNS	I-NP	O
are	be	VBP	B-VP	O
distant	distant	JJ	B-ADJP	O
,	,	,	O	O
but	but	CC	O	O
S1	S1	NN	B-NP	B-protein
,	,	,	O	O
S2	S2	NN	B-NP	B-protein
are	be	VBP	B-VP	O
heard	hear	VBN	I-VP	O
.	.	.	O	O

There	There	EX	B-NP	O
is	be	VBZ	B-VP	O
no	no	DT	B-NP	O
murmurs	murmur	NNS	I-NP	O
,	,	,	O	O
gallops	gallop	NNS	B-NP	O
,	,	,	O	O
or	or	CC	O	O
rubs	rub	NNS	B-NP	O
.	.	.	O	O

JVP	JVP	NN	B-NP	B-protein
can	can	MD	B-VP	O
not	not	RB	I-VP	O
be	be	VB	I-VP	O
determined	determine	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
crackles	crackle	NNS	B-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
base	base	NN	I-NP	O
.	.	.	O	O

Abdomen	Abdoman	NNS	B-NP	O
is	be	VBZ	B-VP	O
markedly	markedly	RB	B-ADJP	O
obese	obese	JJ	I-ADJP	O
with	with	IN	B-PP	O
significant	significant	JJ	B-NP	O
lateral	lateral	JJ	I-NP	O
edema	edema	NN	I-NP	O
particularly	particularly	RB	B-ADVP	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
side	side	NN	I-NP	O
where	where	WRB	B-ADVP	O
his	his	PRP$	B-NP	O
pannus	pannus	NN	I-NP	O
tends	tend	VBZ	B-VP	O
to	to	TO	I-VP	O
fall	fall	VB	I-VP	O
.	.	.	O	O

There	There	EX	B-NP	O
is	be	VBZ	B-VP	O
significant	significant	JJ	B-NP	O
scrotal	scrotal	JJ	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
scrotum	scrotum	NN	I-NP	O
appears	appear	VBZ	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
about	about	IN	B-NP	O
7	7	CD	I-NP	O
inches	inch	NNS	I-NP	O
in	in	IN	B-PP	O
diameter	diameter	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
bilateral	bilateral	JJ	B-NP	O
3	3	CD	I-NP	O
+	+	SYM	O	O
pitting	pit	VBG	B-VP	O
leg	leg	NN	B-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
2	2	CD	B-NP	O
+	+	SYM	I-NP	O
DP	DP	NN	I-NP	O
pulses	pulse	VBZ	B-VP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
closed	close	VBN	I-VP	O
ulcers	ulcer	NNS	B-NP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
which	which	WDT	B-NP	O
he	he	PRP	B-NP	O
states	state	VBZ	B-VP	O
that	that	WDT	B-NP	O
have	have	VBP	B-VP	O
been	be	VBN	I-VP	O
there	there	RB	B-ADVP	O
for	for	IN	B-PP	O
several	several	JJ	B-NP	O
years	year	NNS	I-NP	O
and	and	CC	O	O
that	that	IN	B-SBAR	O
he	he	PRP	B-NP	O
tends	tend	VBZ	B-VP	O
to	to	TO	I-VP	O
pick	pick	VB	I-VP	O
at	at	IN	B-PP	O
them	them	PRP	B-NP	O
daily	daily	JJ	B-ADJP	O
to	to	TO	B-VP	O
make	make	VB	I-VP	O
them	them	PRP	B-NP	O
bleed	bleed	VB	B-VP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
EXAM	EXAM	NN	I-NP	O
:	:	:	O	O
Sodium	Sodium	NN	B-NP	O
145	145	CD	I-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
3.4	3.4	CD	I-NP	O
,	,	,	O	O
chloride	chloride	NN	B-NP	O
107	107	CD	I-NP	O
,	,	,	O	O
bicarb	bicarb	NN	B-NP	O
21	21	CD	I-NP	O
,	,	,	O	O
BUN	BUN	NN	B-NP	B-DNA
68	68	CD	I-NP	I-DNA
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
5.9	5.9	CD	I-NP	O
,	,	,	O	O
glucose	glucose	NN	B-NP	B-protein
53	53	CD	I-NP	I-protein
,	,	,	O	O
lipase	lipase	NN	B-NP	O
11	11	CD	I-NP	O
,	,	,	O	O
total	total	JJ	B-NP	O
bili	bili	NNS	I-NP	O
1.0	1.0	CD	B-NP	O
,	,	,	O	O
alk	alk	NN	B-NP	O
phos	pho	NNS	I-NP	O
153	153	CD	B-NP	O
,	,	,	O	O
BNP	BNP	NN	B-NP	B-DNA
1663	1663	CD	I-NP	I-DNA
,	,	,	O	O
calcium	calcium	NN	B-NP	O
7.8	7.8	CD	I-NP	O
,	,	,	O	O
phosphate	phosphate	NN	B-NP	O
7.3	7.3	CD	I-NP	O
,	,	,	O	O
magnesium	magnesium	NN	B-NP	O
1.8	1.8	CD	I-NP	O
,	,	,	O	O
troponin	troponin	NN	B-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
assay	assay	NN	B-NP	O
,	,	,	O	O
white	white	JJ	B-NP	O
blood	blood	NN	I-NP	O
cell	cell	NN	I-NP	O
count	count	NN	I-NP	O
6.2	6.2	CD	B-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
33.3	33.3	CD	I-NP	I-protein
,	,	,	O	O
platelets	platelet	NNS	B-NP	B-cell_type
144	144	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
1.3	1.3	CD	I-NP	I-protein
,	,	,	O	O
BNP	BNP	NN	B-NP	B-protein
was	be	VBD	B-VP	O
1663	1663	CD	B-NP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
x-ray	x-ray	NN	I-NP	B-DNA
showed	show	VBD	B-VP	O
left	left	RB	B-NP	O
lower	low	JJR	I-NP	O
lobe	lobe	NN	I-NP	O
opacification	opacification	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
stand	stand	VB	I-VP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
lateral	lateral	JJ	I-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
.	.	.	O	O

EKG	EKG	NN	B-NP	B-protein
showed	show	VBD	B-VP	O
first-degree	first-degree	JJ	B-NP	O
AV	AV	NN	I-NP	O
block	block	NN	I-NP	O
with	with	IN	B-PP	O
poor	poor	JJ	B-NP	O
R	R	NN	I-NP	O
wave	wave	NN	I-NP	O
progression	progression	NN	I-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
question	question	NN	I-NP	O
of	of	IN	B-PP	O
Q	Q	NN	B-NP	O
waves	wave	NNS	I-NP	O
in	in	IN	B-PP	O
3	3	CD	B-NP	O
and	and	CC	O	O
AVF	AVF	NN	B-NP	B-protein
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
chronic	chronic	JJ	I-NP	O
renal	renal	JJ	I-NP	O
insufficiency	insufficiency	NN	I-NP	O
was	be	VBD	B-VP	O
progressing	progress	VBG	I-VP	O
likely	likely	RB	B-ADJP	O
for	for	IN	B-PP	O
several	several	JJ	B-NP	O
reasons	reason	NNS	I-NP	O
including	include	VBG	B-PP	O
his	his	PRP$	B-NP	O
chronic	chronic	JJ	I-NP	O
hydronephrosis	hydronephrosis	NN	I-NP	O
.	.	.	O	O

his	his	PRP$	B-NP	O
focal	focal	JJ	I-NP	O
segmental	segmental	JJ	I-NP	O
glomerular	glomerular	JJ	I-NP	O
sclerosis	sclerosis	NN	I-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
hypertension	hypertension	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
given	give	VBN	I-VP	O
large	large	JJ	B-NP	O
amounts	amount	NNS	I-NP	O
of	of	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
but	but	CC	O	O
he	he	PRP	B-NP	O
failed	fail	VBD	B-VP	O
to	to	TO	I-VP	O
diurese	diurese	VB	I-VP	O
significantly	significantly	RB	B-ADVP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
rose	rise	VBD	B-VP	O
to	to	TO	B-PP	O
approximately	approximately	RB	B-NP	O
7.0	7.0	CD	I-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
a	a	DT	B-NP	O
tunneled	tunnel	VBN	I-NP	O
catheter	catheter	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
by	by	IN	B-PP	O
vascular	vascular	JJ	B-NP	O
surgery	surgery	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
began	begin	VBD	B-VP	O
urinalysis	urinalysis	NN	B-NP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
purpose	purpose	NN	I-NP	O
of	of	IN	B-PP	O
taking	take	VBG	B-VP	O
out	out	RP	B-PRT	O
of	of	IN	B-PP	O
volume	volume	NN	B-NP	O
.	.	.	O	O

Approximately	Approximately	RB	B-NP	O
20	20	CD	I-NP	O
liters	liter	NNS	I-NP	O
of	of	IN	B-PP	O
volume	volume	NN	B-NP	O
were	be	VBD	B-VP	O
taken	take	VBN	I-VP	O
off	off	RP	B-PRT	O
over	over	IN	B-PP	O
several	several	JJ	B-NP	O
days	day	NNS	I-NP	O
of	of	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
hemodialysis	hemodialysis	NN	B-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
venous	venous	JJ	B-NP	O
ultrasound	ultrasound	JJ	I-NP	O
mapping	mapping	NN	I-NP	O
for	for	IN	B-PP	O
likely	likely	JJ	B-NP	O
placement	placement	NN	I-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
permanent	permanent	JJ	I-NP	O
AV	AV	NN	I-NP	O
fistula	fistula	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Pulmonary	Pulmonary	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
wear	wear	VB	I-VP	O
his	his	PRP$	B-NP	O
CPAP	CPAP	NN	I-NP	B-protein
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
severe	severe	JJ	I-NP	O
obstructive	obstructive	JJ	I-NP	O
sleep	sleep	NN	I-NP	O
apnea	apnea	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
breathing	breathing	NN	I-NP	O
improved	improve	VBD	B-VP	O
somewhat	somewhat	RB	B-ADVP	O
during	during	IN	B-PP	O
his	his	PRP$	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
but	but	CC	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
possible	possible	JJ	B-ADJP	O
to	to	TO	B-VP	O
tell	tell	VB	I-VP	O
how	how	WRB	B-ADVP	O
well	well	RB	I-ADVP	O
he	he	PRP	B-NP	O
would	would	MD	B-VP	O
do	do	VB	I-VP	O
if	if	IN	B-SBAR	O
he	he	PRP	B-NP	O
would	would	MD	B-VP	O
attempt	attempt	VB	I-VP	O
to	to	TO	I-VP	O
walk	walk	VB	I-VP	O
again	again	RB	B-ADVP	O
as	as	IN	B-SBAR	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
sedentary	sedentary	JJ	B-ADJP	O
and	and	CC	O	O
in	in	IN	B-PP	O
bed	bed	NN	B-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
entire	entire	JJ	I-NP	O
hospitalization	hospitalization	NN	I-NP	O
except	except	IN	B-PP	O
for	for	IN	B-PP	O
occasionally	occasionally	RB	B-ADVP	O
sitting	sit	VBG	B-VP	O
up	up	RP	B-PRT	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
side	side	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
bed	bed	NN	I-NP	O
and	and	CC	O	O
moving	move	VBG	B-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
bed	bed	NN	I-NP	O
chair	chair	NN	I-NP	O
once	once	RB	B-ADVP	O
or	or	CC	I-ADVP	O
twice	twice	RB	I-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Infectious	Infectious	JJ	B-NP	O
Disease	Disease	NN	I-NP	O
:	:	:	O	O
There	There	EX	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	O	O
clear	clear	JJ	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
critically	critically	RB	B-PP	O
or	or	CC	I-PP	O
on	on	IN	B-PP	O
review	review	NN	B-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
chest	chest	NN	I-NP	O
x-ray	x-ray	NN	I-NP	O
and	and	CC	O	O
therefore	therefore	RB	B-ADVP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
specifically	specifically	RB	I-VP	O
treated	treat	VBN	I-VP	O
for	for	IN	B-PP	O
pneumonia	pneumonia	NN	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
upon	upon	IN	B-PP	O
placement	placement	NN	B-NP	O
of	of	IN	B-PP	O
a	a	DT	B-NP	O
Foley	Foley	NNP	I-NP	O
catheter	catheter	NN	I-NP	O
,	,	,	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
a	a	DT	B-NP	O
significant	significant	JJ	I-NP	O
amount	amount	NN	I-NP	O
of	of	IN	B-PP	O
white	white	JJ	B-NP	B-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
in	in	IN	B-PP	O
the	the	DT	B-NP	O
urine	urine	NN	I-NP	O
and	and	CC	O	O
while	while	IN	B-SBAR	O
the	the	DT	B-NP	O
urine	urine	NN	I-NP	O
culture	culture	NN	I-NP	O
appeared	appear	VBD	B-VP	O
not	not	RB	O	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
negative	negative	JJ	B-ADJP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
treated	treat	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
10-day	10-day	JJ	I-NP	O
course	course	NN	I-NP	O
of	of	IN	B-PP	O
levofloxacin	levofloxacin	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
renally	renally	RB	B-VP	O
adjusted	adjust	VBN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
for	for	IN	B-PP	O
urinary	urinary	JJ	B-NP	O
tract	tract	NN	I-NP	O
infection	infection	NN	I-NP	O
.	.	.	O	O

Foley	Foley	NNP	B-NP	O
catheter	catheter	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
placed	place	VBN	I-VP	O
by	by	IN	B-PP	O
urology	urology	NN	B-NP	O
.	.	.	O	O

Due	Due	JJ	B-PP	O
to	to	TO	I-PP	O
difficulties	difficulty	NNS	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
anatomy	anatomy	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
may	may	MD	B-VP	O
get	get	VB	I-VP	O
hard	hard	JJ	B-ADJP	O
to	to	TO	B-VP	O
place	place	VB	I-VP	O
.	.	.	O	O

Once	Once	NNP	B-NP	O
Foley	Foley	NNP	I-NP	O
catheter	catheter	NN	I-NP	O
was	be	VBD	B-VP	O
removed	remove	VBN	I-VP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
urinate	urinate	VB	I-VP	O
on	on	IN	B-PP	O
his	his	PRP$	B-NP	O
own	own	JJ	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	NNP	B-NP	O
:	:	:	O	O
A.	A.	NN	B-NP	O
Rhythm	Rhythm	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
sotalol	sotalol	NN	B-NP	O
and	and	CC	O	O
a	a	DT	B-NP	O
beta-blocker	beta-blocker	NN	I-NP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
prior	prior	JJ	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
ventricular	ventricular	JJ	B-NP	O
tachycardia	tachycardia	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
episodes	episode	NNS	I-NP	O
while	while	IN	B-SBAR	O
inhouse	inhouse	NN	B-NP	O
on	on	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
electrophysiologist	electrophysiologist	NN	I-NP	O
Dr.	Dr.	NNP	I-NP	O
Marc	Marc	NNP	I-NP	O
C	C	NNP	I-NP	O
Gouin	Gouin	NNP	I-NP	O
suggested	suggest	VBD	B-VP	O
that	that	IN	B-SBAR	O
given	give	VBN	B-PP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
sotalol	sotalol	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
reduced	reduce	VBN	I-VP	O
to	to	TO	B-PP	O
40	40	CD	B-NP	O
mg	mg	NN	I-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
approximately	approximately	RB	B-NP	O
two	two	CD	I-NP	O
hours	hour	NNS	I-NP	O
after	after	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
plan	plan	NN	I-NP	O
was	be	VBD	B-VP	O
to	to	TO	B-VP	O
monitor	monitor	VB	I-VP	O
the	the	DT	B-NP	O
QT	QT	NN	I-NP	O
interval	interval	NN	I-NP	O
and	and	CC	O	O
discontinue	discontinue	VB	B-VP	O
sotalol	sotalol	NN	B-NP	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
QT	QT	NN	I-NP	O
interval	interval	NN	I-NP	O
or	or	CC	O	O
if	if	IN	B-SBAR	O
the	the	DT	B-NP	O
QTC	QTC	NN	I-NP	B-protein
were	be	VBD	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
500	500	CD	B-NP	O
msecs	msec	NNS	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
QTC	QTC	NN	I-NP	B-DNA
was	be	VBD	B-VP	O
monitored	monitor	VBN	I-VP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
and	and	CC	O	O
never	never	RB	B-VP	O
exceeded	exceed	VBD	I-VP	O
500	500	CD	B-NP	O
msecs	msec	NNS	I-NP	O
.	.	.	O	O

Therefore	Therefore	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
sotalol	sotalol	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
continued	continue	VBN	I-VP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
dose	dose	NN	I-NP	O
on	on	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
days	day	NNS	I-NP	O
.	.	.	O	O

B.	B.	NNP	B-NP	O
Ischemia	Ischemia	NNP	I-NP	O
:	:	:	O	O
He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
much	much	RB	I-VP	O
ruled	rule	VBN	I-VP	O
out	out	RP	B-PRT	O
for	for	IN	B-PP	O
MI	MI	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
maintained	maintain	VBN	I-VP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
statin	statin	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
a	a	DT	B-NP	O
beta-blocker	beta-blocker	NN	I-NP	B-protein
.	.	.	O	O

C.	C.	NNP	B-NP	O
Pump	Pump	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
volume	volume	NN	B-NP	O
overloaded	overload	VBN	B-VP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
and	and	CC	O	O
improved	improve	VBN	B-VP	O
after	after	IN	B-PP	O
significant	significant	JJ	B-NP	O
volume	volume	NN	I-NP	O
reduction	reduction	NN	I-NP	O
by	by	IN	B-PP	O
hemodialysis	hemodialysis	NN	B-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
review	review	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
prior	prior	JJ	I-NP	O
cardiac	cardiac	JJ	I-NP	O
echoes	echo	NNS	I-NP	O
showed	show	VBD	B-VP	O
that	that	IN	B-SBAR	O
in	in	IN	B-PP	O
9/30	9/30	CD	B-NP	O
he	he	PRP	B-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
approximately	approximately	RB	B-NP	O
70	70	CD	I-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
2/19	2/19	CD	B-NP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
fell	fall	VBD	B-VP	O
to	to	TO	B-PP	O
about	about	RB	B-NP	O
45	45	CD	I-NP	O
to	to	TO	I-NP	O
50	50	CD	I-NP	O
%	%	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
repeat	repeat	NN	B-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
repeat	repeat	NN	I-NP	O
echocardiogram	echocardiogram	NN	I-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
about	about	RB	B-NP	O
30	30	CD	I-NP	O
to	to	TO	I-NP	O
35	35	CD	I-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
mildly	mildly	RB	I-NP	O
dilated	dilate	VBN	I-NP	O
left	left	JJ	I-NP	O
ventricle	ventricle	NN	I-NP	O
,	,	,	O	O
moderately	moderately	RB	B-ADVP	O
reduced	reduce	VBD	B-VP	O
left	left	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
function	function	NN	I-NP	O
.	.	.	O	O

Akinesis	Akinesis	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
entire	entire	JJ	I-NP	O
apex	apex	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
basal	basal	JJ	I-NP	B-DNA
septum	septum	NN	I-NP	I-DNA
segment	segment	NN	I-NP	I-DNA
and	and	CC	O	O
the	the	DT	B-NP	O
basal	basal	JJ	I-NP	B-DNA
posterior	posterior	JJ	I-NP	I-DNA
segment	segment	NN	I-NP	I-DNA
of	of	IN	B-PP	O
the	the	DT	B-NP	O
heart	heart	NN	I-NP	O
and	and	CC	I-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
anterior	anterior	JJ	I-NP	O
wall	wall	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
anterior	anterior	JJ	I-NP	O
lateral	lateral	JJ	I-NP	O
wall	wall	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
inferior	inferior	JJ	I-NP	O
wall	wall	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
mid	mid	JJ	I-NP	B-DNA
anterior	anterior	JJ	I-NP	I-DNA
septum	septum	NN	I-NP	I-DNA
segment	segment	NN	I-NP	I-DNA
.	.	.	O	O

There	There	EX	B-NP	O
is	be	VBZ	B-VP	O
mild	mild	JJ	B-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
tricuspid	tricuspid	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
and	and	CC	I-NP	O
trace	trace	NN	I-NP	O
aortic	aortic	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
without	without	IN	B-PP	O
any	any	DT	B-NP	O
significant	significant	JJ	I-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
aortic	aortic	JJ	B-NP	O
stenosis	stenosis	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

PhosLo	PhosLo	NN	B-NP	O
1334	1334	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
t.i.d.	t.i.d.	FW	I-ADVP	O
,	,	,	O	O
instructions	instruction	NNS	B-NP	O
to	to	TO	B-VP	O
give	give	VB	I-VP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Heparin	Heparin	NN	B-NP	B-protein
5000	5000	CD	B-NP	I-protein
units	unit	NNS	I-NP	I-protein
subcutaneous	subcutaneous	JJ	B-NP	I-protein
t.i.d.	t.i.d.	NN	I-NP	I-protein
3	3	CD	I-NP	I-protein
.	.	.	O	O

Bactroban	Bactroban	JJ	B-NP	O
topical	topical	JJ	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
,	,	,	O	O
please	please	VB	B-VP	O
apply	apply	RB	B-ADVP	O
to	to	TO	B-PP	O
legs	leg	NNS	B-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Senna	Senna	NNP	B-NP	O
two	two	CD	I-NP	O
tablets	tablet	NNS	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
5	5	CD	I-NP	O
.	.	.	O	O

Lipitor	Lipitor	NN	B-NP	B-protein
40	40	CD	I-NP	I-protein
mg	mg	NN	I-NP	I-protein
p.o.	p.o.	NN	I-NP	I-protein
q.d.	q.d.	NN	I-NP	I-protein
6	6	CD	I-NP	I-protein
.	.	.	O	O

Sotalol	Sotalol	NN	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
,	,	,	O	O
instructions	instruction	NNS	B-NP	O
to	to	TO	B-VP	O
please	please	VB	I-VP	O
give	give	VB	B-NP	O
two	two	CD	B-NP	O
hours	hour	NNS	I-NP	O
after	after	IN	B-PP	O
dialysis	dialysis	NN	B-NP	O
.	.	.	O	O

Also	Also	RB	B-ADVP	O
,	,	,	O	O
please	please	VB	B-VP	O
monitor	monitor	NN	B-NP	O
QT	QT	NN	I-NP	O
interval	interval	NN	I-NP	O
every	every	DT	B-NP	O
three	three	CD	I-NP	O
to	to	TO	I-NP	O
four	four	CD	I-NP	O
days	day	NNS	I-NP	O
and	and	CC	O	O
discontinue	discontinue	VB	B-VP	O
sotalol	sotalol	NN	B-NP	O
if	if	IN	B-SBAR	O
QTC	QTC	NN	B-NP	B-protein
is	be	VBZ	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
500	500	CD	B-NP	O
msec	msec	NN	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Toprol	Toprol	NN	B-NP	O
XL	XL	NN	I-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
8	8	CD	I-NP	O
.	.	.	O	O

Wellbutrin	Wellbutrin	NN	B-NP	O
SR	SR	NN	I-NP	O
150	150	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
9	9	CD	I-NP	O
.	.	.	O	O

Nephrocaps	Nephrocaps	RB	B-NP	O
one	one	CD	I-NP	O
tab	tab	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
10	10	CD	I-NP	O
.	.	.	O	O

Flomax	Flomax	NN	B-NP	O
0.8	0.8	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
11	11	CD	I-NP	O
.	.	.	O	O

Mirapex	Mirapex	NNP	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
q.a.m.	q.a.m.	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
,	,	,	O	O
1	1	CD	B-NP	O
mg	mg	NN	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
12	12	CD	I-NP	O
.	.	.	O	O

Glipizide	Glipizide	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
13	13	CD	I-NP	O
.	.	.	O	O

Lactulose	Lactulose	RB	B-NP	O
30	30	CD	I-NP	O
ml	ml	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.i.d.	q.i.d.	FW	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
constipation	constipation	NN	I-NP	O
.	.	.	O	O

14	14	CD	B-NP	O
.	.	.	O	O

Afrin	Afrin	NNP	B-NP	O
Spray	Spray	NNP	I-NP	O
two	two	CD	B-NP	O
sprays	spray	NNS	I-NP	O
b.i.d.	b.i.d.	VBP	B-VP	O
p.r.n.	p.r.n.	NN	B-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
for	for	IN	B-PP	O
nasal	nasal	JJ	B-NP	O
congestion	congestion	NN	I-NP	O
.	.	.	O	O

15	15	CD	B-NP	O
.	.	.	O	O

Sudafed	Sudafe	VBN	B-NP	O
30	30	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	NN	B-NP	O
as	as	IN	B-PP	O
needed	need	VBN	B-VP	O
for	for	IN	B-PP	O
nasal	nasal	JJ	B-NP	O
congestion	congestion	NN	I-NP	O
.	.	.	O	O

16	16	CD	B-NP	O
.	.	.	O	O

Saline	Saline	NNP	B-NP	O
Spray	Spray	NNP	I-NP	O
two	two	CD	B-NP	O
sprays	spray	NNS	I-NP	O
inhaled	inhale	VBD	B-VP	O
q.	q.	NN	B-NP	O
12h	12h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
for	for	IN	B-PP	O
dry	dry	JJ	B-NP	O
nose	nose	NN	I-NP	O
or	or	CC	O	O
nasal	nasal	JJ	B-NP	O
congestion	congestion	NN	I-NP	O
.	.	.	O	O

17	17	CD	B-NP	O
.	.	.	O	O

Trazodone	Trazodone	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.h.s.	q.h.s.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
insomnia	insomnia	NN	I-NP	O
.	.	.	O	O

18	18	CD	B-NP	O
.	.	.	O	O

Flonase	Flonase	NN	B-NP	O
one	one	CD	I-NP	O
to	to	TO	I-NP	O
two	two	CD	I-NP	O
sprays	spray	NNS	I-NP	O
inhaled	inhale	VBD	B-VP	O
b.i.d.	b.i.d.	JJ	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
for	for	IN	B-PP	O
nasal	nasal	JJ	B-NP	O
congestion	congestion	NN	I-NP	O
.	.	.	O	O

19	19	CD	B-NP	O
.	.	.	O	O

Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.d.	q.d.	FW	I-NP	O
20	20	CD	I-NP	O
.	.	.	O	O

Epogen	Epogen	NN	B-NP	O
40	40	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
units	unit	NNS	I-NP	O
subcutaneous	subcutaneous	JJ	B-NP	O
q.	q.	NN	I-NP	O
week	week	NN	I-NP	O
.	.	.	O	O

21	21	CD	B-NP	O
.	.	.	O	O

Multivitamin	Multivitamin	NN	B-NP	O
therapeutic	therapeutic	JJ	I-NP	O
one	one	CD	I-NP	O
tablet	tablet	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.d.	q.d.	FW	I-NP	O
TO	TO	NN	I-NP	O
DO	DO	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
receive	receive	VB	I-VP	O
hemodialysis	hemodialysis	NN	B-NP	O
three	three	CD	B-NP	O
times	time	NNS	I-NP	O
a	a	DT	B-NP	O
week	week	NN	I-NP	O
on	on	IN	B-PP	O
Tuesdays	Tuesday	NNS	B-NP	O
,	,	,	O	O
Thursdays	Thursday	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Saturdays	Saturday	NNS	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Ezra	Ezra	NNP	I-NP	O
Ozuna	Ozuna	NNP	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
within	within	IN	B-PP	O
three	three	CD	B-NP	O
or	or	CC	I-NP	O
four	four	CD	I-NP	O
weeks	week	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
QTC	QTC	NN	I-NP	O
intervals	interval	NNS	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
monitored	monitor	VBN	I-VP	O
every	every	DT	B-NP	O
week	week	NN	I-NP	O
while	while	IN	B-SBAR	O
at	at	IN	B-PP	O
rehab	rehab	NN	B-NP	O
or	or	CC	B-PP	O
at	at	IN	B-PP	O
a	a	DT	B-NP	O
regular	regular	JJ	I-NP	O
doctor	doctor	NN	I-NP	O
's	's	POS	B-NP	O
appointment	appointment	NN	I-NP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
to	to	TO	B-VP	O
ensure	ensure	VB	I-VP	O
that	that	IN	B-SBAR	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
500	500	CD	I-NP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
it	it	PRP	B-NP	O
is	be	VBZ	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
500	500	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
the	the	DT	B-NP	O
frequency	frequency	NN	I-NP	O
of	of	IN	B-PP	O
sotalol	sotalol	NN	B-NP	O
administration	administration	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
decreased	decrease	VBN	I-VP	O
in	in	IN	B-SBAR	O
order	order	NN	O	O
to	to	TO	B-VP	O
maintain	maintain	VB	I-VP	O
a	a	DT	B-NP	O
QTC	QTC	NNP	I-NP	O
of	of	IN	B-PP	O
less	less	JJR	B-NP	O
than	than	IN	I-NP	O
500	500	CD	I-NP	O
msecs	msec	NNS	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
1-5500630	1-5500630	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Jacob	Jacob	NNP	B-NP	O
A.	A.	NNP	I-NP	O
Lenton	Lenton	NNP	I-NP	O
MD	MD	NNP	I-NP	O
Cardiac	Cardiac	NNP	I-NP	O
Arrhythmia	Arrhythmia	NNP	I-NP	O
Service	Service	NNP	I-NP	O
,	,	,	O	O
Muin	Muin	NNP	B-NP	O
University	University	NNP	I-NP	O
Hospital	Hospital	NNP	I-NP	O
Querwall	Querwall	NNP	I-NP	O
Highway	Highway	NNP	I-NP	O
CC	CC	NNP	I-NP	O
:	:	:	O	O
Matt	Matt	NNP	B-NP	O
Dyer	Dyer	NNP	I-NP	O
M.D.	M.D.	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
CRNKOVICH	CRNKOVICH	NN	B-NP	O
,	,	,	O	O
LOREN	LOREN	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
PEPION	PEPION	NN	B-NP	O
,	,	,	O	O
DICK	DICK	NNP	B-NP	O
COLLIN	COLLIN	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
5878429	5878429	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
7/23/04	7/23/04	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
7/23/04	7/23/04	CD	B-NP	O

